Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Insects|May 24, 2024
Molecular Correlates of Diapause in Aphidoletes aphidimyzaXiaoyan Dai, Yu Wang, Yan Liu, et al.
Optics Letters|March 16, 2011
Coherent beam combination of 1.08 kW fiber amplifier array using single frequency dithering techniqueYanxing Ma, Xiaolin Wang, Jinyong Leng, et al.
Diabetes, Obesity & Metabolism|April 20, 2022
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trialWenying Yang, Xiaolin Dong, Qingju Li, et al.
Clinical Pharmacokinetics|June 7, 2023
Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal ImpairmentHengli Zhao, Zhirui Zhao, Kun He, et al.
Diabetes, Obesity & Metabolism|October 19, 2020
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trialLinong Ji, Xiaolin Dong, Yiming Li, et al.
Analytical Chemistry|August 15, 2017
Intuitive Label-Free SERS Detection of Bacteria Using Aptamer-Based in Situ Silver Nanoparticles SynthesisWeicun Gao, Bo Li, Ruizhi Yao, et al.
Experimental and Therapeutic Medicine|December 30, 2017
Effectiveness of C5a aptamers in a TNBS-induced colitis mouse modelZhiping Li, Xiwen Wang, Man Chen, et al.
Diabetes, Obesity & Metabolism|August 13, 2021
DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulinYu Pei, Bue R Agner, Bin Luo, et al.
CNS Neuroscience & Therapeutics|August 4, 2024
Increased opioid consumption in neoadjuvant immunotherapy plus chemotherapy for patients with non-small-cell lung cancer: A multicenter, prospective cohort studyKaiyuan Wang, Jianxu Er, Yu Zhang, et al.
Diabetes, Obesity & Metabolism|January 6, 2026
Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight (LIGHT 1): A randomized, double-blind, placebo-controlled, ascending-dose phase 2a trialFei Gao, Mingxia Yuan, Nianrong Mi, et al.
Pageof 9